Cachexia and Sarcopenia

Sarcopenia

Volumn , Issue , 2012, Pages 141-153

  Muscaritoli, Maurizio ^a   Lucia, Simone ^a   Fanelli, Filippo Rossi ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Age related sarcopenia, distinction from forms of muscle depletion; Cachexia and sarcopenia, multidimensional clinical evaluations needed; Cachexia and sarcopenia, sharing analogy in pathogenic phenotypic; Comorbidities, as differentiated from disability; EWGSOP, clinical definition and consensus diagnostic criteria; Human aging, body function decline, intrinsic extrinsic; Human aging, whether as physiological or pathologic; Sarcopenia concept, operational with diagnostic criteria needed; Sarcopenia, and aging, muscle mass function loss; Sarcopenia, poor outcomes mobility disorders disability quality of life

Indexed keywords

EID: 84884689788     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118338032.ch10     Document Type: Chapter

References (70)

1. Strehler BL. (1997) Time, Cells, and Aging. Academic Press, New York, USA.
2. Goto M. (2008) Inflammaging (inflammation + aging): A driving force for human aging based on an evolutionarily antagonistic pleiotropy theory? Biosci Trends. 2(6), 218-230.
3. Narici MV, Maffulli N. (2010) Sarcopenia: characteristics, mechanisms and functional significance. Br Med Bull 95, 139-159.
4. Thomas DR. (2007) Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. Clin Nutr. 26(4), 389-399.
5. Janssen I, Shepard DS, Katzmarzyk PT, et al. (2004) The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 52(1), 80-85.
6. Cederholm TE, Bauer JM, Boirie Y, et al. (2011) Toward a definition of sarcopenia. Clin Geriatr Med. 27(3), 341-353. doi: 10.1016/j.cger.2011.04.001.
7. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. (2010) European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 39(4), 412-423.
8. Cruz-Jentoft AJ, Landi F, Topinková E, et al. (2010) Understanding sarcopenia as a geriatric syndrome. Curr Opin Clin Nutr Metab Care. 13(1), 1-7.
9. Barendregt K, Soeters PB, Allison SP. (2004) Influence of malnutrition on physiological function. In: Sobotka L, editor. Basics in clinical nutrition. 3rd ed. Galen, p.18-20.
10. Biolo G, Ciocchi B, Stulle M, et al. (2005) Metabolic consequences of physical inactivity. J Ren Nutr 15(1), 49-53.
11. Biolo G, Heer M, Narici M, et al. (2003) Microgravity as a model of ageing. Curr Opin Clin Nutr Metab Care 6(1) 31-40.
12. Evans WJ, Morley JE, Argilés J, et al. (2008) Cachexia: a new definition. Clin Nutr 27(6), 793-799.
13. von Haehling S, Anker SD. (2010) Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachex Sarcopenia Muscle 1(1), 1-5.
14. Muscaritoli M, Anker SD, Argilés J, et al. (2010) Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) 'cachexia-anorexia in chronic wasting diseases' and 'nutrition in geriatrics'. Clin Nutr 29(2), 154-159.
15. Marín Caro MM, Laviano A, Pichard C. (2007) Nutritional intervention and quality of life in adult oncology patients. Clin Nutr 26(3), 289-301.
16. Fearon KC. (1992) The mechanisms and treatment of weight loss in cancer. Proc Nutr Soc 51(2), 251-265.
17. Tisdale MJ. (2009) Mechanisms of cancer cachexia. Physiol Rev 89(2), 381-410.
18. KrasnowSM, Marks DL. (2010) Neuropeptides in the pathophysiology and treatment of cachexia. Curr Opin Support Palliat Care 4(4), 266-271.
19. Schols A, Broekhuizen R, Weling-Scheepers CA, et al. (2005) Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 82, 53-59.
20. Mantovani G. (2006) Cachexia related to multiple cause. In: Mantovani G, editor. Cachexia and wasting: a modern approach. Springer, p. 161-162.
21. Vigano A, Donaldson N, Higginson IJ, et al. (2004) Quality of life and survival prediction interminal cancer patients: a multicenter study. Cancer 101(5), 1090-1098.
22. Vigano A, Dorgan M, Buckingham J, et al. (2000) Survival prediction in terminal cancer patients:a systematic review of the medical literature. Palliat Med 14(5), 363-374.
23. Tisdale MJ. (2010) Cancer cachexia. Curr Opin Gastroenterol 26(2), 146-151.
24. Costelli P, Baccino FM. (2003) Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP-ubiquitin-dependent proteolysis. Curr Opin Clin Nutr Metab Care 6(4), 407-412.
25. Aversa Z, Bonetto A, Penna F, et al. (2011) Changes in Myostatin Signaling in Non-Weight- Losing Cancer Patients. Ann Surg Oncol. Apr 26. [Epub ahead of print] 26. Penna F, Bonetto A, Muscaritoli M, et al. (2010) Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved? Int J Cancer 127(7), 1706-1717.
26. Aversa Z, Bonetto A, Costelli P, et al. (2011) ß-hydroxy-ß-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia. Int J Oncol 38(3), 713-720. doi: 10.3892/ijo.2010.885.
27. Goldspink G. (2006) Impairment of IGF-I gene splicing and MGF expression associated with muscle wasting. Int J Biochem Cell Biol 38(3), 481-489.
28. Saini A, Al-Shanti N, Stewart CE. (2006) Waste management-cytokines, growth factors and cachexia. Cytokine Growth Factor Rev 17(6), 475-486.
29. Tisdale MJ. (2003) The "cancer cachectic factors". Support Care Cancer 11(2), 73-78.
30. Barendregt K, Soeters PB, Allison SP, et al. (2004) Simple and stress starvation. In: Sobotka L, editor. Clinical nutrition, 3rd ed. Galen, p. 107-113.
31. Tan BH, Fearon KC. (2008) Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 11(4), 400-407.
32. Laviano A, Meguid MM, Rossi Fanelli F. (2003) Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 4, 686-694.
33. Ribaudo JM, Cella D, Hahn EA, et al. (2000) Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res 9, 1137-1146.
34. FearonKet al. (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5), 489-495.
35. Rochon PA, Katz JN, Morrow LA, et al. (1996) Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. A prospective comparison of three comorbidity indices. Med Care 34(11), 1093-1101.
36. Gross PA, Stein MR, van Antwerpen C, et al. (1991) Comparison of severity of illness indicators in an intensive care unit. Arch Intern Med 151(11), 2201-2205.
37. Stineman MG, Escarce JJ, Tassoni CJ, et al. (1998) Diagnostic coding and medical rehabilitation length of stay: their relationship. Arch Phys Med Rehabil 79(3), 241-248.
38. de Groot V, Beckerman H, Lankhorst GJ, et al. (2003) How to measure comorbidity. a critical review of available methods. J Clin Epidemiol 56(3), 221-229.
39. Lee JS, Auyeung TW, Kwok T, et al. (2007) Associated factors and health impact of sarcopenia in older chinese men and women: a cross-sectional study. Gerontology 53(6), 404-410.
40. Rolland Y, Czerwinski S, Abellan Van Kan G, et al. (2008) Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging 12(7), 433-450.
41. Fried LP, Ferrucci L, Darer J, et al. (2004) Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 59(3), 255-263.
42. Hoffman C, Rice D, Sung HY. (1996) Persons with chronic conditions. Their prevalence and costs. JAMA 276(18), 1473-1479.
43. Wu SY, Green A. (2000) Projection of Chronic Illness Prevalence and Cost Inflation.Washington DC, RAND Health.
44. Bocognano A, Durnesni JS, Frerot L, et al. (1999) Sant'e, soins et protection sociale en 1998. CREDES Edition.
45. Fried LP, Bandeen-Roche K, Kasper JD, et al. (1999) Association of comorbidity with disability in older women: the Women's Health and Aging Study. J Clin Epidemiol 52, 27-37.
46. Davies DF, Shock NW. (1950) Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 29, 496-507.
47. Wesson LG Jr. (1969) Renal hemodynamics in physiological states. In Physiology of the Human Kidney. New York: Grune and Stratton, 96-108.
48. Macías-Núñez JF, López-Novoa JM. (2008) Physiology of the healthy aging kidney. In: Macías- Núñez JF, Cameron JS, Oreopoulos DM, eds. The Aging Kidney in Health and Disease. New York: Springer, 93-112.
49. Hollenberg NK, Rivera A, Meinking T, et al. (1999) Age, renal perfusion, and function in island-dwelling indigenous Kuna Amerinds of Panama. Nephron 82, 131-138.
50. Hoang K, Tan JC, Derby G, et al. (2003) Determinants of glomerular hypofiltration in aging humans. Kidney Int 64, 1417-1424.
51. National Kidney Foundation Kidney Disease Outcomes Quality Initiative. (2002) Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Am J Kidney Dis (suppl 1) 39, s1-s266.
52. Rifkin DE, Sarnak MJ. (2009) Does inflammation fuel the fire in CKD? Am J Kidney Dis 53(4), 572-575.
53. Workeneh BT, Mitch WE. (2010) Review of muscle wasting associated with chronic kidney disease. Am J Clin Nutr 91(4), 1128S-1132S.
54. Yao H, Rahman I. (2009) Current concepts on the role of inflammation in COPD and lung cancer. Curr Opin Pharmacol 9(4), 375-383.
55. Cornwell WD, Kim V, Song C, et al. (2010) Pathogenesis of inflammation and repair in advanced COPD. Semin Respir Crit Care Med 31(3), 257-266.
56. Witasp A, Carrero JJ, Heimbürger O, et al. (2011) Increased expression of pro-inflammatory genes in abdominal subcutaneous fat in advanced chronic kidney disease patients. J Intern Med 269(4), 410-9. doi: 10.1111/j.1365-2796.2010.02293.x.
57. Mantovani A, Allavena P, Sica A, et al. (2008) Cancer-related inflammation. Nature 454(7203), 436-444.
58. Grivennikov SI, Greten FR, Karin M. (2010) Immunity, inflammation, and cancer. Cell 140(6), 883-899.
59. Fu M. (2009) Inflammation in chronic heart failure: what is familiar, what is unfamiliar? Eur J Heart Fail 11(2), 111-112.
60. Parish RC, Evans JD. (2008) Inflammation in chronic heart failure. Ann Pharmacother 42(7), 1002-1016.
61. Donath MY, Shoelson SE. (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11(2), 98-107.
62. Hotamisligil GS. (2006) Inflammation and metabolic disorders. Nature 444(7121), 860-867.
63. Espinola-Klein C, Gori T, Blankenberg S, et al. (2011) Inflammatory markers and cardiovascular risk in the metabolic syndrome. Front Biosci 16, 1663-1674.
64. Monteiro R, Azevedo I. (2010) Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm, doi: 10.1155/2010/289645. Epub 2010 Jul 14.
65. Seymour JM, Spruit MA, Hopkinson NS, et al. (2010) The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J 36(1), 81-8.
66. Schols AM. Pulmonary cachexia. Int J Cardiol. 2002 Sep;85(1): 101-110.
67. Leal VO, Mafra D, Fouque D, Anjos LA. (2011) Use of handgrip strength in the assessment of the muscle function of chronic kidney disease patients on dialysis: a systematic review. Nephrol Dial Transplant 26(4), 1354-1360.
68. Park SW, Goodpaster BH, Lee JS, et al. (2009) Health, Aging, and Body Composition Study. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care 32(11), 1993-1997.
69. Park SW, Goodpaster BH, Strotmeyer ES, et al. (2007) Health, Aging, and Body Composition Study. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care 30(6), 1507-1512.
70. Krause MP, Riddell MC, Hawke TJ. (2011) Effects of type 1 diabetes mellitus on skeletal muscle: clinical observations and physiological mechanisms. Pediatr Diabetes 12(4 Pt 1), 345-64. doi: 10.1111/j.1399-5448.2010.00699.x.